Nan Fang Du Shi Bao·2025-12-22 23:14Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition aims to create an efficient ecosystem platform for "industry, academia, research, medicine, and finance" while focusing on financial empowerment and overseas expansion as key drivers for industry development [2] - The exhibition featured deep discussions on how finance can empower innovation in the medical device industry, with insights from industry leaders like Lang Tao from China Resources Pharmaceutical Group, who outlined two clear paths: strategic investments in innovative medical device companies and mergers to quickly acquire mature product lines and core technologies [2] - A series of high-profile investment and financing matchmaking activities were held, including the "Breaking the Deadlock · Establishing New" CGT project financing roadshow, which selected eight leading companies in gene editing and cell therapy to engage with investors [3] Group 2 - Jingtai Technology signed a $59.9 billion cooperation order with an overseas pharmaceutical company, marking the largest order in the field of AI-enabled drug development [3] - The "Intelligent Medical, Riding the Waves Overseas" forum focused on the core issues of intelligent and global development in the medical industry, gathering over 80 industry leaders and experts to discuss how AI and digital technologies can empower Chinese medical enterprises for high-quality overseas expansion [4] - The "Breaking the Deadlock · Going Overseas" forum highlighted case studies of seven pioneering companies from the Hong Kong Science Park, emphasizing collaboration and experience sharing to provide replicable pathways for mainland innovative products to enter the global market [4]